The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-18 and is reviewed periodically as new material appears.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
=== Organisms === Polystyrene is generally considered to be non-biodegradable. However, certain organisms are able to degrade it, albeit very slowly. In 2015, researchers discovered that mealworms, the larvae form of the darkling beetle Tenebrio molitor, could digest and subsist healthily on a diet of EPS. About 100 mealworms could consume between 34 milligrams (0.52 gr) and 39 milligrams (0.60 gr) of this white foam in a day. The droppings of mealworm were found to be safe for use as soil for crops. In 2016, it was also reported that superworms (Zophobas morio) may eat expanded polystyrene (EPS). A group of high school students in Ateneo de Manila University found that compared to Tenebrio molitor larvae, Zophobas morio larvae may consume greater amounts of EPS over longer periods of time. In 2022 scientists identified several bacterial genera, including Pseudomonas, Rhodococcus and Corynebacterium, in the gut of superworms that contain encoded enzymes associated with the degradation of polystyrene and the breakdown product styrene. The bacterium Pseudomonas putida is capable of converting styrene oil into the biodegradable plastic PHA. This may someday be of use in the effective disposing of polystyrene foam. It is worthy to note the polystyrene must undergo pyrolysis to turn into styrene oil.
Pharmer.org—A non-profit site providing detailed descriptions of most narcotic analgesics List of controlled substances Archived 2021-04-25 at the Wayback Machine, some of which are classified as "narcotics", in the U.S. Controlled Substances Act (CSA). Not all of the classified ones are chemically narcotic, as described at the top of this page. M. C. Cooke (1860), The Seven Sisters of Sleep, Popular History of the Seven Prevailing Narcotics of the World.
As part of the Interkosmos space program, allies of the Soviet Union, including the People's Republic of Bulgaria, actively participated in the research and deployment of space technologies from the 1960s until the end of communism in 1989-1990 in the Eastern Bloc. The Institute of Cryobiology and Lyophilization (now the Institute of Cryobiology and Food Technology), founded in 1973 as a part of the Bulgarian Academy of Sciences, produced space food for the purposes of the program. The menu includes traditional Bulgarian dishes such as tarator, sarma, musaka, lyutenitza, kiselo mlyako, dried vegetables and fruits, etc.
Benefits of space exploration NASA STI Program, for NASA's Science and Technical Information program NASA Tech Briefs, for NASA innovations that are not necessarily commercial yet Timeline of United States inventions Timeline of United States discoveries National Inventors Hall of Fame Science and technology in the United States Technological and industrial history of the United States Space Foundation Space Certification Space Technology Hall of Fame
Sources: en.wikipedia.org
== History == The uterine-contracting properties of the principle that would later be named oxytocin were discovered by British pharmacologist Henry Hallett Dale in 1906, and its milk ejection property was described by Ott and Scott in 1910 and by Schafer and Mackenzie in 1911. In 1909 the first clinical use of oxytocin was performed by William Blair-Bell to induce childbirth in patients with complications. By the 1920s, oxytocin and vasopressin had been isolated from pituitary tissue and given their current names. Oxytocin's molecular structure was determined in 1952. In the early 1950s, American biochemist Vincent du Vigneaud found that oxytocin is made up of nine amino acids. He identified its amino acid sequence, the first polypeptide hormone to be sequenced. In 1953, du Vigneaud carried out the synthesis of oxytocin, the first polypeptide hormone to be synthesized. Du Vigneaud was awarded the Nobel Prize in Chemistry in 1955 for his work. Further work on different synthetic routes for oxytocin, as well as the preparation of analogues of the hormone (e.g. 4-deamido-oxytocin) was performed in the following decade by Iphigenia Photaki.
== Management == Treatment requires identifying and removing any causative medications and correcting any underlying electrolyte abnormalities. While TdP often self-resolves, cardioversion may be indicated if patients become hemodynamically unstable, as evidenced by signs such as hypotension, altered mental status, chest pain, or heart failure. Intravenous magnesium sulfate has been proven to be highly effective for both the treatment and prevention of TdP. Managing patients with TdP is dependent on the patient's stability. Vital signs, level of consciousness, and current symptoms are used to assess stability. Patients who are stable should be managed by removing the underlying cause and correcting electrolyte abnormalities, especially hypokalemia. An EKG should be obtained, a cardiac monitor should be attached, IV access should be established, supplemental oxygen should be given, and blood samples should be sent for appropriate studies. Patients should be continually re-evaluated for signs of deterioration until the TdP resolves. In addition to correcting the electrolyte abnormalities, magnesium given intravenously has also been shown to be helpful. Magnesium sulfate given as a 2 g IV bolus mixed with D5W can be given over a period of 15 minutes in patients without cardiac arrest Atrial pacing or administering isoproterenol can normalize the heart rate. Unstable patients exhibit signs of chest pain, hypotension, elevated heart rate, and/or heart failure. Patients who develop cardiac arrest will be pulseless and unconscious.
=== Partial vacuum method (ultra sniffer test) === In contrast to the Helium charged vacuum test, the partial vacuum method, the ultra sniffer test gas method (UST-method) uses a partial vacuum effect, so that gas tightness of the test sample can be detected at normal pressure with the same sensitivity as the helium charged vacuum test with helium gas helium. The method has a sensitivity of 10−12 Pa·m3·s−1. Similar to the classical Helium charged sniffer test the test sample is enclosed in a bag, but in contrast to the classic method, the bag is exposed with a helium-free gas, so that the helium concentration inside the bag can reduced from 5·10−7 to 10−12 Pa·m3·s−1. This sensitivity corresponds to a theoretical gas loss of 1 cm3 in 3000 years. The UST method can be used very economically for the ad hoc testing of test samples. The test system can be set up easily, with normal pneumatic items, such as valves and plastic hoses. For the embedding of the test samples, a simple plastic bag is sufficient. The UST method was also used for the leak testing of component of the fusion experiment Wendelstein 7-X in Germany.
Sources: en.wikipedia.org
=== Dietary sources === Arginine is classified as a semiessential or conditionally essential amino acid, depending on the developmental stage and health status of the individual. Preterm infants are unable to synthesize arginine internally, making the amino acid nutritionally essential for them. Most healthy people do not need to supplement with arginine because it is a component of all protein-containing foods and can be synthesized in the body from glutamine via citrulline. Additional, dietary arginine is necessary for otherwise healthy individuals temporarily under physiological stress, for example during recovery from burns, injury or sepsis, or if either of the major sites of arginine biosynthesis, the small intestine and kidneys, have reduced function, because the small bowel does the first step of the synthesizing process and the kidneys do the second. Arginine is an essential amino acid for birds, as they do not have a urea cycle. For some carnivores, for example cats, dogs and ferrets, arginine is essential, because after a meal, their highly efficient protein catabolism produces large quantities of ammonia which need to be processed through the urea cycle, and if not enough arginine is present, the resulting ammonia toxicity can be lethal. This is not a problem in practice, because meat contains sufficient arginine to avoid this situation. Animal sources of arginine include meat, dairy products, and eggs, and plant sources include seeds of all types, for example grains, beans, and nuts.
=== Finnish === Examples of long words that have been in everyday use in the Finnish language are kolmivaihekilowattituntimittari which means "three-phase kilowatt hour meter" (31 letters), liikekannallepanotarkastuskierros ("mobilization inspection round", 33 letters), peruspalveluliikelaitoskuntayhtymä ("a public utility of a municipal federation for provision of basic services", 34 letters), and lentokonesuihkuturbiinimoottoriapumekaanikkoaliupseerioppilas "airplane jet turbine engine auxiliary mechanic non-commissioned officer student" (61 letters), an actual military term, although one which has been deprecated. The longest military term in current use is vastatykistömaalinosoitustutkakalustojärjestelmäinsinöörierikoisupseeri "counter-artillery targeting radar systems engineer specialist officer" with 71 characters, with 2 more if grammatically incorrect extra hyphens added for readability are counted. If conjugated forms are allowed, even longer real words can be made. Allowing derivatives and clitics allows the already lengthy word to grow even longer, although the usability of the word starts to degrade. Because Finnish uses free forming of composite words, new words can even be formed during a conversation. One can add nouns after each other without breaking grammar rules. If one allows artificial constructs as well as using clitics and conjugated forms, one can create even longer words: such as kumarreksituteskenteleentuvaisehkollaismaisekkuudellisennesk- enteluttelemattomammuuksissansakaankopahan (102 letters), which was created by Artturi Kannisto.
== Research == Luvesilocin is under development for the treatment of postpartum depression (PPD), treatment-resistant depression, and other psychiatric disorders. As of September 2025, it has reached phase 2 clinical trials for these indications. A phase 3 trial is planned for 2026. The drug is being developed by Reunion Neuroscience (formerly known as Field Trip Health).
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.